Abstract
Migraine and cluster headache are two highly disabling primary headache disorders, each characterized by distinct clinical phases. Both conditions feature a premonitory phase that precedes the onset of pain or the emergence of cluster bouts, and the symptoms occurring during this stage may provide critical insight into their underlying pathophysiology. This narrative review aims to synthesize current evidence on the premonitory phase of migraine and cluster headache, including its clinical manifestations, neurobiological mechanisms, and potential implications for early or pre-emptive therapeutic strategies. Migraine patients frequently experience premonitory symptoms before the onset of headache, and multimodal neuroimaging indicates that migraine initiation involves coordinated functional alterations within hypothalamic–brainstem circuits.
Introduction
For decades, headache research and treatment focused almost exclusively on the "pain phase." However, most patients experience a constellation of non-pain symptoms—like yawning, neck stiffness, or mood changes—hours or even days before the first throb of pain. This "premonitory phase" represents a critical window for understanding the initiation and progression of primary headaches. While well-recognized in migraine, this phase is not yet formally defined for Cluster Headache (CH) in the International Classification of Headache Disorders (ICHD-3). Understanding whether these early symptoms are mere warnings or the actual start of the neural cascade leading to pain is essential for shifting from reactive to pre-emptive management.
Clinical Phenotyping and Temporal Profiles
Prospective studies indicate that 77% to 88% of migraineurs experience identifiable premonitory symptoms. These symptoms typically last between 6 to 10 hours, though they can extend up to 48 hours before pain onset. Common manifestations include photophobia, phonophobia, mood changes, and difficulty concentrating.
A significant insight from recent research is the re-evaluation of "triggers." Evidence suggests that many perceived triggers, such as bright light, may actually be early premonitory symptoms (e.g., premonitory photophobia) occurring because the attack has already initiated in the brain.
The Unique Case of Cluster Headache
In Cluster Headache, roughly 83% of patients report premonitory phenomena. The review distinguishes between two distinct early phases: pre-cluster symptoms, which emerge days or weeks before a "bout" of headaches begins, and pre-attack symptoms, which develop 10 to 60 minutes before a specific spike of pain.
A unique feature of CH is "shadow pain"—a dull, aching sensation in the same location as the upcoming intense attack. This likely represents early activation of the trigeminal-autonomic reflex.
Pathophysiological Mechanisms: The Hypothalamic Hub
Neuroimaging studies (fMRI, PET, and ASL) consistently identify the hypothalamus as "Ground Zero" for both migraine and CH initiation. In CH, hypothalamic involvement is linked to circadian dysregulation, explaining the rhythmic nature of attacks. While both disorders involve hypothalamic-brainstem circuits, CH is more focal and lateralized, whereas migraine involves broader sensory and limbic network reorganization. Genetic studies further support this, identifying mutations in circadian genes like CLOCK and PER3 that may influence these rhythmic patterns.
Therapeutic Potential and Future Directions
The premonitory phase offers a "window of opportunity" for intervention. The PRODROME trial demonstrated that 46% of patients taking ubrogepant during the premonitory phase did not progress to moderate or severe pain, compared to 29% in the placebo group.
However, challenges remain. In CH, the pre-attack window is often too short (10-60 minutes) for oral medications to be absorbed and take effect before pain peaks. There is also a risk of medication overuse if symptoms do not always lead to a full attack. Future research must focus on identifying objective biomarkers—via wearable technology or biochemical assays—to signal the start of this phase accurately.
Conclusion
The premonitory phase represents the actual initiation of the headache attack in the brain. By elucidating the shared and divergent mechanisms involving hypothalamic dysfunction and trigeminal-autonomic activation, clinicians can move toward a paradigm of truly pre-emptive intervention, stopping the "pain engine" before it fully revs up.
Summary updated